The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study - 13/01/21
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Objective |
The aim of this study was to evaluate clinicopathological features, oncological outcome and prognostic factors for recurrence in advanced stage uterine serous carcinoma (USC) patients.
Methods |
Patients with 2009 International Federation of Gynecology and Obstetrics stage III&IV uterine serous carcinoma were enrolled from 4 gynecologic oncology centers and a study group was created. Response to therapy was evaluated according to the WHO criteria. Progression-free survival (PFS) and overall survival (OS) estimates were determinated by using the Kaplan-Meier method. Survival curves were compared with the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model.
Results |
Entire cohort included 63 patients. Median age of cohort was 64 years. Thirty-five (55.6%) patients were stage IV. Lymphadenectomy was performed in 57 (90.5%) patients and lymph node metastasis was positive in 45 (71.4%) patients. Maximal cytoreduction (no residue tumor) was achieved in 53 (84.1%) patients. However, optimal cytoreduction (residue tumor ≤1 cm) was achieved in 6 (9.5%) patients and suboptimal cytoreduction (residue tumor >1 cm) was achieved in 3 (4.8%) patients. Median follow-up time was 19 (range;1-152) months. Complete clinical response was obtained in 58 (92.1%) patients after standard adjuvant therapy. Disease failure was detected in 25 patients. Study group had a 2-year PFS of 51% and 2-year OS of 80%. On multivariate analysis, performing lymphadenectomy was an independent prognostic factor for PFS (Odds ratio: 24.794, 95% Confidence Interval: 4.214-145.869; p < 0.001).
Conclusion |
Lymphadenectomy should be a part of the standard surgical therapy in advanced stage USC.
Le texte complet de cet article est disponible en PDF.Keywords : Advanced stage, lymphadenectomy, uterine serous carcinoma, survival
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?